What is a practical algorithm for restarting antiplatelet therapy after an intracerebral hemorrhage?

Practical Algorithm for Restarting Antiplatelet Therapy After Intracerebral Hemorrhage

For patients with ICH who were on antiplatelet therapy before their bleed, restart antiplatelet monotherapy after 24 hours if they have a strong indication (like prior major adverse cardiovascular events), as this approach does not increase recurrent ICH risk and may actually reduce it. 1

Step-by-Step Decision Algorithm

Step 1: Determine if Patient Has Strong Indication to START

Start antiplatelet therapy if:

• ICH occurred while on antithrombotic therapy AND
• History of major adverse cardiovascular events (MACE) such as prior stroke, MI, or coronary stent AND
• No atrial fibrillation

Timing: Can restart beyond 24 hours after ICH symptom onset 1. Chinese guidelines suggest within a few days 1, while observational data supports safety of early resumption within 30 days 1, 2.

Step 2: Determine if Patient Has Strong Indication to AVOID

Avoid antiplatelet therapy if:

• Recurrent lobar ICH (suggests cerebral amyloid angiopathy) 1
• Major extracranial hemorrhage history 1
• ICH not associated with prior antithrombotic use AND no history of MACE 1

Step 3: For All Other Patients (Gray Zone)

Make individualized risk-benefit assessment based on:

Higher risk of ischemic events (favors restarting):

• Recent coronary stent placement
• Prior ischemic stroke or TIA
• Ischemic heart disease
• Younger age
• Male sex 3

Higher risk of recurrent ICH (favors avoiding):

• Lobar ICH location
• Imaging markers of cerebral amyloid angiopathy
• Multiple prior ICH episodes
• Older age

Step 4: If Patient Has Atrial Fibrillation

Do NOT use antiplatelet therapy. Instead, consider:

• Enrollment in ongoing RCTs of anticoagulation (ENRICH-AF, ASPIRE, PRESTIGE-AF) 1
• Left atrial appendage occlusion
• Anticoagulation restart if high ischemic risk outweighs bleeding risk

Medication Selection

Use antiplatelet monotherapy only 1:

• Aspirin (most studied)
• Clopidogrel
• Dipyridamole

Avoid dual antiplatelet therapy - associated with 43% higher early mortality risk compared to single agent 4

Key Evidence Supporting This Algorithm

The RESTART trial (2019) showed that starting antiplatelet therapy after ICH:

• Reduced recurrent ICH risk by 49% (adjusted HR 0.51, not increased as feared) 1
• Reduced major cardiovascular events by 35% initially 1
• Was safe even in high-risk patients who had ICH while on antithrombotics 1

A 2025 meta-analysis confirmed 46% reduction in recurrent ICH with early antiplatelet resumption, with no increase in ischemic complications 5.

Common Pitfalls to Avoid

1. Don't wait too long - The UK/Ireland guidelines permit restarting beyond 24 hours 1, and early resumption (≤30 days) appears as safe as delayed resumption 2

2. Don't use dual antiplatelet therapy - Significantly increases mortality risk 4

3. Don't restart in patients with atrial fibrillation - These patients need anticoagulation consideration, not antiplatelet therapy 1

4. Don't assume all lobar ICH patients should avoid antiplatelets - Only those with recurrent lobar ICH or clear amyloid angiopathy markers 1

5. Don't forget that most ICH survivors currently receive no antithrombotic therapy - Only 10.4% are prescribed antiplatelet therapy at discharge despite many having indications 3

Strength of Evidence

Current guidelines from USA, Canada, China, and UK/Ireland all give Level B recommendations (moderate evidence) supporting antiplatelet resumption in appropriate patients 1. The evidence is permissive but not yet definitive, as RESTART was a pilot-phase trial with limitations including small sample size and imprecise effect estimates 1.

The balance clearly favors restarting antiplatelet therapy in patients with prior MACE and ICH associated with antithrombotic use, as the annual MACE rate after ICH is 4-8% and these events carry high mortality 1.